Olema Pharmaceuticals' (OLMA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Olema Pharmaceuticals (NASDAQ:OLMA - Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $30.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. cut their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Friday, March 28th. Oppenheimer reissued an "outperform" rating and set a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.

Olema Pharmaceuticals Trading Up 6.2 %

NASDAQ:OLMA traded up $0.33 on Monday, hitting $5.62. The company's stock had a trading volume of 983,181 shares, compared to its average volume of 862,824. Olema Pharmaceuticals has a one year low of $2.86 and a one year high of $16.62. The firm has a market capitalization of $384.03 million, a P/E ratio of -2.57 and a beta of 2.10. The stock has a fifty day moving average of $4.20 and a two-hundred day moving average of $6.66.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. As a group, sell-side analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Institutional Trading of Olema Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $30,000. Hsbc Holdings PLC bought a new position in Olema Pharmaceuticals during the 4th quarter worth $58,000. Teacher Retirement System of Texas acquired a new position in Olema Pharmaceuticals in the 4th quarter valued at $60,000. Virtus ETF Advisers LLC lifted its position in shares of Olema Pharmaceuticals by 43.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company's stock valued at $62,000 after acquiring an additional 3,185 shares during the period. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth $62,000. Institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.